Study Condition(s): Non-small Cell Lung Cancer

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Study Alias: JFCQ

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02451930 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizumab in participants with stage IV NSCLC.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

The duration of your participation will depend on the duration of your study treatment, your disease progression, and follow-up visits
  • Participant must have stage IV Non-Small Cell Lung Cancer

  • Participant must have progressed after 1 platinum-based chemotherapy regimen. Participant whose tumor has an EGFR activating mutation or ALK translocations must have prior treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and anaplastic lymphoma kinase (ALK) inhibitors

  • Participant must have tumor tissue available for biomarker analyses

  • Participant must not have surgery within 30 days of study start

  • Participant must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte-associated antigen-4 antibody or EGFR-directed monoclonal antibody (mAb)

  • Participant must not have undergone chest irradiation within 4 weeks prior to receiving study treatment

  • Participant must not be currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device

  • Participant must not be pregnant or breastfeeding

Where to Participate

20 locations are currently available of 20 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.